Pathway-based polygenic risk implicates GO: 17144 drug metabolism in recurrent depressive disorder
Anna R. Docherty,
T. Bernard Bigdeli,
Alexis K. Edwards,
Daniel E Adkins,
John S Anderson,
Kenneth S Kendler,
Posted 26 Oct 2017
bioRxiv DOI: 10.1101/209544
Posted 26 Oct 2017
The Psychiatric Genomics Consortium (PGC) has made major advances in the molecular etiology of MDD, confirming that MDD is highly polygenic, with any top risk loci conferring a very small proportion of variance in case-control status. Pathway enrichment results from PGC meta-analyses can also be used to help inform molecular drug targets. Prior to any knowledge of molecular biomarkers for MDD, drugs targeting molecular pathways have proved successful in treating MDD. However, it is possible that with information from PGC analyses, examining specific molecular pathway(s) implicated in MDD can further inform our study of molecular drug targets. Using a large case-control GWAS based on low-coverage whole genome sequencing (N = 10,640), we derived polygenic risk scores for MDD and for MDD specific to each of over 300 molecular pathways. We then used these data to identify sets of scores significantly predictive of case status, accounting for critical covariates. Over and above global polygenic risk for MDD, polygenic risk within the GO: 17144 drug metabolism pathway significantly predicted recurrent depression. In transcriptomic analyses, two pathway genes yielded suggestive signals at FDR q-values = .054: CYP2C19 (family of Cytochrome P450) and CBR1 (Carbonyl Reductase 1). Because the neuroleptic carbamazepine is a known inducer of CYP2C19, future research might examine whether drug metabolism PRS has any influence on clinical presentation and treatment response. Overall, results indicate that pathway-based risk might inform treatment of severe depression. We discuss limitations to the generalizability of these preliminary findings, and urge replication in future research.
- Downloaded 357 times
- Download rankings, all-time:
- Site-wide: 61,988 out of 118,796
- In genetics: 3,007 out of 5,149
- Year to date:
- Site-wide: 90,681 out of 118,796
- Since beginning of last month:
- Site-wide: 95,641 out of 118,796
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!